达布拉芬尼
曲美替尼
医学
肺癌
内科学
克拉斯
液体活检
肿瘤科
数字聚合酶链反应
威罗菲尼
活检
神经母细胞瘤RAS病毒癌基因同源物
无进展生存期
临床研究阶段
间隙
前瞻性队列研究
MEK抑制剂
后天抵抗
生物标志物
实体瘤疗效评价标准
癌症研究
V600E型
黑色素瘤
不利影响
病理
癌症
化疗
作者
Alessandro Leonetti,Monica Pluchino,Roberta Minari,Francesco Passiglia,Elio Gregory Pizzutilo,Diego Cortinovis,Luca Toschi,Francesco Gelsomino,Stefano Frega,Giulio Metro,Lorenzo Belluomini,Michele Montrone,Andrea Camerini,Alessandro Bertolini,Editta Baldini,Francesca Mazzoni,Emilio Bria,Federica Bertolini,Alessandro Del Conte,Paola Bordi
摘要
PURPOSE Dabrafenib plus trametinib is a standard first-line treatment for BRAF V600E–mutated non–small cell lung cancer (NSCLC). The LiBRA study aimed to explore the role of liquid biopsy in detecting and monitoring BRAF V600E mutation, assessing its potential to predict treatment response and emerging resistance. MATERIALS AND METHODS This prospective multicenter study enrolled patients with BRAF V600E–mutated NSCLC treated with first-line dabrafenib plus trametinib. Plasma samples were collected at baseline (t0), after 4 weeks (t1), and longitudinally until disease progression (PD). BRAF V600E was monitored by digital droplet PCR (ddPCR). Next-generation sequencing (NGS) was performed at t0 and PD to identify resistance mechanisms. RESULTS Forty patients were enrolled. Dabrafenib plus trametinib achieved an overall response rate of 42.5%, with a median progression-free survival (PFS) and overall survival (OS) of 8.3 and 21.1 months, respectively. At t0, BRAF V600E was detectable by ddPCR in 24 (62%) of 39 patients. Among 21 shedders evaluated at t1, 17 (81%) cleared the mutation. Higher baseline BRAF V600E allele frequency was associated with shorter PFS (hazard ratio [HR], 1.09, P = .013) and OS (HR, 1.10, P = .010), whereas clearance at t1 correlated with longer PFS (8.3 v 1.4 months, P < .001) and OS (10.5 v 2.2 months, P < .001). Biological PD anticipated radiologic/clinical PD by a median of 4.9 weeks (IQR, 1.4-9.8). Baseline EGFR and MET CNVs were associated with shorter PFS and OS. Resistance mechanisms at PD included NRAS , KRAS , TP53 mutations and MET , EGFR , ERBB2 CNVs. CONCLUSION The LiBRA study supports liquid biopsy as a prognostic and monitoring tool in BRAF V600E–mutated NSCLC undergoing targeted therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI